The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin

AIDS

Volumn 10, Issue 2, 1996, Pages 159-165

  Merigan, Thomas C ^a,c   Hirsch, Robert L ^b   Fisher, Alan C ^b   Meyerson, Linda A ^b   Goldstein, Gideon ^b   Winters, Mark A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Immunobiology Research Institute   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asymptomatic; Disease progression; HIV RNA; Resistance; Therapy; Thymopentin; Viral load; Zidovudine

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CD4 ANTIGEN; IMMUNOSTIMULATING AGENT; RNA DIRECTED DNA POLYMERASE; THYMOPENTIN; VIRUS ENZYME; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0030062761     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199602000-00005     Document Type: Article

References (52)

1. Masur H, Ognibene FP, Yarchoan R, et al.: CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989, 111:223-231.
2. Gardner LI Jr, Brundage JF, McNeil JG, et al.: Predictors of HIV-1 disease progression in early- and late-stage patients: the US Army natural history cohort. J Acquir Immune Defic Syndr 1992, 5:782-793.
3. Keel IPM, Krol A, Klein MR, et al.: Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis 1994, 169:1236-1243.
4. Drabick JJ, Williams WJ, Tang DB, Sun W, Chung RC, Military Medical Consortium for Applied Retroviral Research: CD4 lymphocyte decline and survival in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1992, 8:2039-2047.
5. Schellekens PTA, Tersmette M, Roos MTL, et al.: Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992, 6:665-669
6. Easterbrook PJ, Emami J, Gazzard B: Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. AIDS 1993, 7:959-967.
7. Farzadegan H, Chmiel JS, Odaka N, et al.: Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4+ lymphocyte number, and AIDS-free time. J Infect Dis 1992, 166:1217-1222.
8. Cao Y, Qin L, Zhang L, Safrit J, Ho D: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201-208.
9. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
10. Hogervorst E, Jurriaans S, de Wolf F, et al.: Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995, 171:811-821.
11. Loveday C, Hill A: Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995, 345:790-791.
12. Verhofstede C, Reniers S, Van Wanzeele F, Plum J: Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS 1994, 8:1421-1427.
13. Koot M, Keel IPM, Vos AHV, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
14. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD: A cross-sectional comparison of persons with syncytium-and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993, 168:1374-1379.
15. Osmond DH, Shiboski S, Bacchetti P, Winger EE, Moss AR: Immune activation markers and AIDS prognosis. AIDS 1991, 5:505-511.
16. 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS 1990, 4:207-214.
17. 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection. Arch Intern Med 1990, 150:73-77.
18. 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. AIDS 1993, 7:813-821.
19. 2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet 1992, 339:1436-1440.
20. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC: Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994, 169:416-419.
21. Holodniy M, Katzenstein D, Winters M, et al.: Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acquir Immune Defic Syndr 1993, 6:366-369.
22. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L: Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995, 9:159-163.
23. 3. 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC, January 1995 [abstract LB31].
24. 3. 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC, January 1995 [abstract LB34].
25. 3. 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC, January 1995 [abstract LB35].
26. 2-microglobulins as surrogate markers. X International Conference on AIDS. Yokohama, August 1994 [abstract 254B].
27. Welles SL, Coombs R, Crumpacker CS, et al.: Issues of internal and external validity in retrospective studies of virus load and clinical outcome. Presented at Surrogate Markers of HIV: Strategies and Issues for Selection and Use. Arlington, October 1994.
28. Choi S, Lagakos SW, Schooley RT, Volberding PA: CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993, 118:674-680.
29. Seligmann M, Warrell DA, Aboulker J-P, et al.: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
30. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC: A mutation of human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993, 167:526-532.
31. Kozal MJ, Shafer RW, Winters MA, et al.: HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Def Syndr 1994, 7:832-838.
32. Montaner JSG, Singer J, Schechter MT, et al.: Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicentre Canadian AZT trial. AIDS 1993, 7:189-196.
33. Tudor-Williams G, St Clair MH, McKinney RE, et al.: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992, 339:15-19.
34. Japour AJ, Welles S, D'Aquila RT, et al.: Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995, 171:1172-1179.
35. 3: a double-blind placebo-controlled trial. J Acquir Immune Defic Syndr Hum Retroviruses 1995, 8:279-288.
36. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36:3-15.
37. Volberding PA, Lagakos SW, Koch MA, et al.: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990, 322:941-949.
38. Fischl MA, Richman DD, Hansen N, et al.: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 1990, 112:727-737.
39. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
40. Collett D: Modelling Survival Data in Medical Research. London: Chapman and Hall; 1994.
41. SAS Institute: SAS/STAT Users Guide, Version 6, Fourth Edn, Vol 2. Cary, NC: SAS Institute, Inc.; 1989.
42. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
43. Barcellini W, Meroni PL, Frasca D, et al.: Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. Clin Exp Immunol 1987, 67:537-543.
44. Silvestris F, Gernone A, Frassanito MA, Dammacco F: Immunologic effects of long- term thymopentin treatment in patients with HIV-induced lymphadenopathy syndrome. J Lab Clin Med 1989, 113:139-144.
45. Conant MA, Calabrese LH, Thompson SE, et al.: Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects: results of a double-blind, placebo-controlled study. AIDS 1992, 6:1335-1339.
46. Meroni PL, Barcellini W, Frasca D, et al.: In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production. Clin Immunol Immunopathol 1987, 42:151-159.
47. Cillari E, Milano S, Perego R, et al.: Modulation of IL-2, IFN-γ, TNF-α and IL-4 production in mice of different ages by thymopentin. Int J Immunopharmacol 1992, 14:1029-1035.
48. Cillari E, Milano S, Dieli M, et al.: Thymopentin reduces the susceptibility of aged mice to cutaneous leishmaniasis by modulating CD4 T-cell subsets. Immunology 1992, 76:362-366.
49. 32-36 (TP5) on cytotoxic lymphocyte precursor units (CLP-U). I. Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation. J Immunol 1980, 124:1861-1865.
50. 32-36 (TP-5). Thymus 1983, 5:375-382.
51. Cappel R, de Cuyper F, De Neef K, Höbel W, Bolla K: Effect of thymopentin on the mortality and immune response after an experimental herpes simplex infection in mice. Surv Immunol Res 1985, 4 (suppl 1):48-57.
52. Ventura MT, Ottolenghi A, De Mitrio V, Antonaci S, Bonomo L: Prostaglandin and lymphokine-mediated effects on natural killer cytotoxicity in human immunodeficiency virus-positive haemophiliacs. Med Sci Res 1988, 16:639-640.